Our latest analysis on The next wave of biosimilars, highlighting a significant opportunity as biologics $150B approach patent expiry in this decade.

With biosimilars capturing over 50%+ market share within three years of launch, the sector is set for continued expansion. By 2032, 118 biologics worth ~$235B will lose exclusivity, yet only a fraction currently have biosimilars in clinical development — presenting a significant untapped market.

Strategic partnerships will be critical to sharing the high costs, navigating the regulatory hurdles, leveraging mutual expertise for faster and more efficient development therefore, building a comprehensive portfolio to compete with innovators like Amgen and Pfizer.

You can download the presentation here.